GF-ONE 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of GF-ONE supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF082025001

Key analytical results include:

• Assay Content: 11.18 mg
• Identification – Retention Time: 1.00
• Identification – Spectrum: 1
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: 0.0130 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

GF-ONE is a synthetic peptide compound frequently studied in controlled laboratory environments investigating metabolic signalling and hormone-mediated regulatory systems.

The compound belongs to a class of peptide analogues associated with incretin hormone research and metabolic regulatory pathways.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its well-characterised peptide structure and stable analytical profile, GF-ONE has become a commonly referenced compound in experimental metabolic and peptide signalling research models.

Compound Overview

GF-ONE is a synthetic peptide analogue designed to interact with glucagon-like peptide-1 (GLP-1) receptor signalling systems.

In biochemical research, GLP-1 signalling pathways are investigated for their role in metabolic regulation, endocrine signalling and cellular energy balance.

Research involving GF-ONE frequently focuses on how peptide analogues interact with receptor-mediated signalling networks involved in metabolic regulation.

These studies allow scientists to investigate peptide-mediated regulatory mechanisms that influence cellular metabolic communication pathways.

Historical Background and Scientific Context

Scientific interest in incretin hormones increased substantially during the late twentieth century as researchers explored endocrine signalling systems involved in metabolic regulation.

During the 1980s and 1990s glucagon-like peptide-1 (GLP-1) was identified as an important signalling hormone involved in metabolic communication between organs.

Subsequent research led to the development of synthetic peptide analogues designed to investigate GLP-1 receptor signalling pathways.

GF-ONE later emerged as one of the peptide analogues used in laboratory models exploring incretin-related signalling systems and metabolic regulatory pathways.

Mechanistic Focus in Research

Within experimental laboratory settings, GF-ONE is often studied in relation to incretin-related signalling pathways and peptide hormone regulatory networks.

Research investigations commonly explore the compound in experimental models examining:

• GLP-1 receptor signalling pathways
• Metabolic hormone regulatory systems
• Peptide hormone interaction dynamics
• Cellular metabolic signalling networks
• Intracellular metabolic regulation pathways
• Comparative peptide analogue research
• Hormone-mediated cellular regulatory mechanisms

These experimental models allow scientists to investigate molecular signalling mechanisms involved in metabolic regulation and peptide-mediated cellular communication.

Research Applications

In controlled research environments, GF-ONE may be utilised in experimental models designed to explore peptide hormone signalling and metabolic regulatory systems.

Examples of research applications include:

• Metabolic signalling pathway research
• Peptide hormone receptor studies
• Cell signalling pathway analysis
• Molecular metabolic regulation studies
• Comparative peptide analogue evaluation
• Biochemical signalling network modelling
• Controlled in vitro metabolic research

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Verified and analysed with Liquilabs s.r.o. Czechia
Purity greater than 99.8 percent with validated assay content 11.18 mg
GLP-1 receptor peptide with defined analytical profile
No detectable heavy metals or microbial contamination
Endotoxin level detected but below 0.01 EU per mg
Batch GF082025001 – Published January 2026
EU shipments include bacteriostatic water
For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.